NewEdge Advisors’s Dare Bioscience DARE Stock Holding History

NewEdge Advisors’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$5	–	3843
2024 Q1	$5	Hold	1	–	–	﹤0.01%	3791
2023 Q4	$3	Buy	+1	New	+$5	﹤0.01%	3729

Other funds holding DARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

NewEdge Advisors's DARE Position: Q2 2024 in Review

NewEdge Advisors sold out of Dare Bioscience (DARE) in Q2 2024, closing a stake of 1 share — an estimated $5 sold.

NewEdge Advisors first reported a position in DARE in Q4 2023 and held it in 2 quarters. The position peaked at $5 in Q1 2024. 27 funds tracked by Wall St. Rank hold DARE as of Q2 2024.

NewEdge Advisors reported no remaining Dare Bioscience position as of Q2 2024 after selling out during the quarter.
NewEdge Advisors sold 1 Dare Bioscience share in Q2 2024, an estimated $5.
NewEdge Advisors first reported a position in Dare Bioscience in Q4 2023 and held it in 2 quarters.
NewEdge Advisors's Dare Bioscience position peaked at $5 in Q1 2024.
27 funds tracked by Wall St. Rank held Dare Bioscience as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.